Thomas J Velenosi
Overview
Explore the profile of Thomas J Velenosi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yan T, Yan N, Xia Y, Sawaswong V, Zhu X, Dias H, et al.
J Clin Invest
. 2024 Apr;
134(7).
PMID: 38557493
Metabolic dysfunction-associated steatohepatitis (MASH) - previously described as nonalcoholic steatohepatitis (NASH) - is a major driver of liver fibrosis in humans, while liver fibrosis is a key determinant of all-cause...
2.
Sidor N, Velenosi T, Lajoie G, Filler G, House A, Weir M, et al.
ACS Omega
. 2023 May;
8(17):15160-15167.
PMID: 37151562
Glomerular filtration rate (GFR) is the most widely used tool for the measurement of kidney function, but endogenous biomarkers such as cystatin C and creatinine have limitations. A previous metabolomic...
3.
Lim Y, Tonial N, Hartjes E, Haig A, Velenosi T, Urquhart B
Biomed Pharmacother
. 2023 May;
163:114787.
PMID: 37126930
Background And Purpose: Cisplatin-induced nephrotoxicity manifests as acute kidney injury (AKI) in approximately one third of patients receiving cisplatin therapy. Current measures of AKI are inadequate in detecting AKI prior...
4.
Velenosi T, Krausz K, Hamada K, Dorsey T, Ambs S, Takahashi S, et al.
NPJ Precis Oncol
. 2022 Oct;
6(1):70.
PMID: 36207498
Triple-negative breast cancer (TNBC) patients receive chemotherapy treatment, including doxorubicin, due to the lack of targeted therapies. Drug resistance is a major cause of treatment failure in TNBC and therefore,...
5.
Velenosi T, Ben-Yakov G, Podszun M, Hercun J, Etzion O, Yang S, et al.
Gastroenterology
. 2022 Mar;
162(7):1990-2003.
PMID: 35283114
Background & Aims: Hepatic energy metabolism is a dynamic process modulated by multiple stimuli. In nonalcoholic fatty liver disease (NAFLD), human studies typically focus on the static fasting state. We...
6.
Meister J, Bone D, Knudsen J, Barella L, Velenosi T, Akhmedov D, et al.
Nat Commun
. 2022 Jan;
13(1):22.
PMID: 35013148
Activation of the sympathetic nervous system causes pronounced metabolic changes that are mediated by multiple adrenergic receptor subtypes. Systemic treatment with βadrenergic receptor agonists results in multiple beneficial metabolic effects,...
7.
Brocker C, Kim D, Melia T, Karri K, Velenosi T, Takahashi S, et al.
Nat Commun
. 2020 Nov;
11(1):5847.
PMID: 33203882
Exploring the molecular mechanisms that prevent inflammation during caloric restriction may yield promising therapeutic targets. During fasting, activation of the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) promotes the utilization...
8.
Kucey A, Velenosi T, Tonial N, Tieu A, RaoPeters A, Urquhart B
Pharmacol Res Perspect
. 2019 May;
7(3):e00475.
PMID: 31049204
Chronic kidney disease (CKD) is characterized by progressive reduction in kidney function over time. CKD affects greater than 10% of the population and its incidence is on the rise due...
9.
Velenosi T, Thomson B, Tonial N, RaoPeters A, Mio M, Lajoie G, et al.
Sci Rep
. 2019 May;
9(1):6831.
PMID: 31048706
The diagnosis and prognosis of chronic kidney disease (CKD) currently relies on very few circulating small molecules, which can vary by factors unrelated to kidney function. In end-stage renal disease...
10.
Takahashi S, Tanaka N, Fukami T, Xie C, Yagai T, Kim D, et al.
Hepatol Commun
. 2018 Dec;
2(12):1567-1582.
PMID: 30556042
Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths worldwide, and an association between altered bile acid (BA) metabolism, down-regulation of farnesoid X receptor (FXR), which is a master...